| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 1.2MM | +54% |
| Operating Income | -55.9MM | - |
| Operating Expenses | 57.1MM | - |
| Net Income | -49.5MM | - |
| R&D | 35.7MM | +96% |
| G&A | 21.4MM | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m. ET. The webcast of the presentation will be accessible here an
CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to Patrick Horn, M.D., Ph.D., the company’s newly appointed chief medical officer. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the co
―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage bioph
Investors who take an interest in Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) should definitely note that the CEO...
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the Leerink Partners Global Biopharma Conference, being held in Miami, FL on Wednesday, March 13, 2024 at 9:20 a.m. ET. Management will also participate in one-on-o
Fulcrum Therapeutics ( NASDAQ:FULC ) Full Year 2023 Results Key Financial Results Net loss: US$97.3m (loss narrowed by...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript February 27, 2024 Fulcrum Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.44. FULC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to Fulcrum […]
Q4 2023 Fulcrum Therapeutics Inc Earnings Call
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 9.09% and 34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Anticipates Topline Data from Phase 3 REACH Trial in Q4 2024; Strengthens Cash Position